These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28002117)

  • 21. Optimal timing and diagnostic adequacy of hepatocyte phase imaging with gadoxetate-enhanced liver MRI.
    Bashir MR; Breault SR; Braun R; Do RK; Nelson RC; Reeder SB
    Acad Radiol; 2014 Jun; 21(6):726-32. PubMed ID: 24717550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous Gadoxetate Disodium Administration Reduces Breath-holding Capacity in the Hepatic Arterial Phase: A Multi-Center Randomized Placebo-controlled Trial.
    McClellan TR; Motosugi U; Middleton MS; Allen BC; Jaffe TA; Miller CM; Reeder SB; Sirlin CB; Bashir MR
    Radiology; 2017 Feb; 282(2):361-368. PubMed ID: 27509544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced fibrosis: Correlation between pharmacokinetic parameters at dynamic gadoxetate-enhanced MR imaging and hepatocyte organic anion transporter expression in rat liver.
    Lagadec M; Doblas S; Giraudeau C; Ronot M; Lambert SA; Fasseu M; Paradis V; Moreau R; Pastor CM; Vilgrain V; Daire JL; Van Beers BE
    Radiology; 2015 Feb; 274(2):379-86. PubMed ID: 25289480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Respiratory-motion artefacts in liver MRI following injection of gadoxetate disodium and gadobenate dimeglumine: an intra-individual comparative study in cirrhotic patients.
    Furlan A; Close ON; Borhani AA; Wu YH; Heller MT
    Clin Radiol; 2017 Jan; 72(1):93.e1-93.e6. PubMed ID: 27633725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function.
    Karageorgis A; Lenhard SC; Yerby B; Forsgren MF; Liachenko S; Johansson E; Pilling MA; Peterson RA; Yang X; Williams DP; Ungersma SE; Morgan RE; Brouwer KLR; Jucker BM; Hockings PD
    PLoS One; 2018; 13(5):e0197213. PubMed ID: 29771932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age dependence of spleen- and muscle-corrected hepatic signal enhancement on hepatobiliary phase gadoxetate MRI.
    Matoori S; Froehlich JM; Breitenstein S; Doert A; Pozdniakova V; Koh DM; Gutzeit A
    Eur Radiol; 2016 Jun; 26(6):1889-94. PubMed ID: 26334505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gadoxetate uptake as a possible marker of hepatocyte damage after liver resection-preliminary data.
    Bickelhaupt S; Studer P; Kim-Fuchs C; Candinas D; Froehlich JM; Patak MA
    Clin Radiol; 2013 Nov; 68(11):1121-7. PubMed ID: 23932672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of intravenous gadoxetate disodium and flip angle on hepatic proton density fat fraction estimation with six-echo, gradient-recalled-echo, magnitude-based MR imaging at 3T.
    Park CC; Hamilton G; Desai A; Zand KA; Wolfson T; Hooker JC; Costa E; Heba E; Clark L; Gamst A; Loomba R; Middleton MS; Sirlin CB
    Abdom Radiol (NY); 2017 Apr; 42(4):1189-1198. PubMed ID: 28028556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining hyperpolarized
    Ohliger MA; von Morze C; Marco-Rius I; Gordon J; Larson PEZ; Bok R; Chen HY; Kurhanewicz J; Vigneron D
    Magn Reson Med; 2017 Jun; 77(6):2356-2363. PubMed ID: 27298073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. cDNA Microarray Analysis and Influx Transporter OATP1B1 in Liver Cells After Exposure to Gadoxetate Disodium, a Gadolinium-based Contrast Agent in MRI Liver Imaging.
    Lu CC; Chen WK; Chiang JH; Tsai YF; Juan YN; Lin PC; Tyan YS; Yang JS
    In Vivo; 2018; 32(3):677-684. PubMed ID: 29695578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reproducibility of the aortic input function (AIF) derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of the kidneys in a volunteer study.
    Mendichovszky IA; Cutajar M; Gordon I
    Eur J Radiol; 2009 Sep; 71(3):576-81. PubMed ID: 19004588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis?
    Sandrasegaran K; Cui E; Elkady R; Gasparis P; Borthakur G; Tann M; Liangpunsakul S
    Eur Radiol; 2018 Oct; 28(10):4215-4224. PubMed ID: 29651764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging.
    Okada M; Imai Y; Kim T; Kogita S; Takamura M; Kumano S; Onishi H; Hori M; Fukuda K; Hayashi N; Wakasa K; Sakamoto M; Murakami T
    J Magn Reson Imaging; 2010 Oct; 32(4):903-13. PubMed ID: 20882621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic Phospholipidosis Is Associated with Altered Hepatobiliary Function as Assessed by Gadoxetate Dynamic Contrast-enhanced Magnetic Resonance Imaging.
    Lenhard SC; Lev M; Webster LO; Peterson RA; Goulbourne CN; Miller RT; Jucker BM
    Toxicol Pathol; 2016 Jan; 44(1):51-60. PubMed ID: 26516164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abdominal vasculature in dynamic contrast-enhanced liver MRI at 3.0T: an intraindividual comparative study using gadoxetate disodium and gadofosveset trisodium.
    Kupczyk PA; Willinek WA; Hadizadeh DR; Traeber F; Gieseke J; Meyer C; Schild HH; Kukuk GM
    Magn Reson Imaging; 2015 Dec; 33(10):1258-1266. PubMed ID: 26271178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing signal intensity correction during evaluation of hepatic parenchymal enhancement on gadoxetate disodium-enhanced MRI: comparison of three methods.
    Onoda M; Hyodo T; Murakami T; Okada M; Uto T; Hori M; Miyati T
    Eur J Radiol; 2015 Mar; 84(3):339-345. PubMed ID: 25543887
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A LC-MS/MS method to evaluate the hepatic uptake of the liver-specific magnetic resonance imaging contrast agent gadoxetate (Gd-EOB-DTPA) in vitro and in humans.
    Jia J; Keiser M; Nassif A; Siegmund W; Oswald S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Apr; 891-892():20-6. PubMed ID: 22391331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of magnetic resonance elastography and gadoxetate disodium-enhanced magnetic resonance imaging for the evaluation of hepatic fibrosis.
    Choi YR; Lee JM; Yoon JH; Han JK; Choi BI
    Invest Radiol; 2013 Aug; 48(8):607-13. PubMed ID: 23538889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of flip angle for optimization of image quality of gadoxetate disodium-enhanced biliary imaging at 1.5 T.
    Kim S; Mussi TC; Lee LJ; Mausner EV; Cho KC; Rosenkrantz AB
    AJR Am J Roentgenol; 2013 Jan; 200(1):90-6. PubMed ID: 23255746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.